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Cell-mediated immune injury in the kidney: Acute nephritis Induced in
the rat by azobenzenearsonate. Cell-mediated immune mechanisms have
long been suspected of playing an important role in the pathogenesis of
various renal diseases. An animal model of active nephritis secondary
to an exogenous antigen that requires antigen presentation to immune-
competent T cells has not been developed. Consequently, the potential
of kidney cells to serve as effective antigen presenting cells after an
exposure to a therapeutic, biological, or environmental agent in the
intact animal has not been documented. The present experiments were
designed to demonstrate the capacity of the kidney to become the target
for cell-mediated immune injury. A model system has been developed
whereby a chemically reactive form of the hapten azobenzenearsonate
is introduced directly into the left kidney of pre-immunized Brown
Norway rats. Previous studies have shown that this form of the hapten
requires active antigen presentation but no intracellular processing,
since the reactive form of the hapten modifies directly surface ex-
pressed proteins. Delayed hypersensitivity was demonstrated in the
actively immunized animals by standard lymphocyte stimulation index
and by in vivo skin testing. Peak foot pad swelling of 220 13 x 10-2
mm in response to the hapten was observed between days 11 and 14 as
compared to <10 x 10—2 mm in the contralateral foot injected with
vehicle alone and <20 x l0_2 mm in response to azobenzenearsonate
injection in animals immunized with adjuvant alone. The exposure of
the kidney to the hapten in the primed animal results in an active
unilateral granulomatous nephritis with marked destruction of tubules
and glomeruli. On average, 71.5 5.2% of the renal cortex is affected
by the inflammatory process in the actively immunized animals, com-
pared to only 8.1 3.8% in controls. The disease can be reproduced
qualitatively by adoptive transfer of T cells but not by passive antibody
administration to naive recipients. These studies demonstrate that
intrinsic kidney cells can act as effective antigen presenting cells in the
intact animal and that the kidney can become the target of a cell-
mediated immune injury.
Over the past several decades, numerous investigators have
contributed significantly to the study of the mechanisms and
mediators of antibody-initiated renal injury through extensive
analyses of several disease models. In contrast, experimental
studies on cell-mediated immune injury to the kidney in re-
sponse to exogenous antigens have been rather limited [1].
Little or no information is available on the capacity of the
kidney to process and present exogenous antigens to specific T
cells and on the tissue response that results from such an
interaction. Recent in vitro studies with kidney-derived cells
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have suggested that such cells possess the ability to process and
present complex antigenic substances to T cell hybridomas.
This capacity was demonstrated by Wuthrich and Rubin-Kelley
and their collaborators for virus-transformed mouse proximal
tubule cells [2, 3], by Hagerty and Allen for primary cultures of
mouse proximal tubules cells [4], and by Mendrick, Kelly and
Rennke for passaged rat glomerular epithelial and mesangial
cells [5].
Cell-mediated immune mechanisms have long been suspected
of playing a role in the pathogenesis of allograft rejection,
drug-induced interstitial nephritides, and some forms of glomer-
ulonephritides in humans. Direct confirmation that such a
mechanism is responsible for the acute interstitial inflammation
seen in patients after exposure to a drug or other exogenous
substances is still largely missing [6]. The extensive studies by
Neilson and Kelly and collaborators on murine models of
spontaneous autoimmune interstitial nephritis [7—15] and those
by Wilson et al [16—18] and Neilson et al [19—22] on the
anti-tubular basement membrane disease in Brown Norway rats
clearly suggest that tubulointerstitial damage can occur in the
context of an altered autoimmunity. Likewise, in some forms of
glomerular injury, where the formation of cellular crescents
dominates the morphological expression of the disease, a pre-
dominance of monocytes and macrophages has also led to
postulate a cell-mediated process. The only model studied in
detail to date that involves an exogenous antigen is the accel-
erated nephrotoxic serum nephntis in the rat. Although most rat
strains do not develop overt crescents in this experimental
model, Schreiner et al described the participation of monocytes
during the early cellular events [23, 24], and Bhan et al [25, 26]
and Holdsworth et al [27—30] were able to document the
participation of T cells in the pathogenesis of this form of
glomerular injury.
In the present studies, we set out to establish a model of
cell-mediated injury to a relatively well-studied hapten with the
aim of determining the mechanisms of cell injury, the type of
cells and mediators involved, and the structural and functional
expression of this process. In this model we used azobenzene-
arsonate (ABA), a hapten that can be introduced directly into
cell surface components of potential target cells [31—34],
thereby bypassing the step of intracellular antigen processing
and subsequent re-expression of epitopes in the context of
products of the major histocompatibility complex [35—43]. Our
studies indicate that resident kidney cells have the capacity to
present an exogenous antigen such as ABA and that the
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resultant disease process has all the characteristics of a delayed
type hypersensitivity.
Methods
General experimental design
The experiments were designed to demonstrate a role for
cell-mediated immunity and, in particular, a role for delayed
type hypersensitivity (DH) in the pathogenesis of inflammatory
renal processes in the Brown Norway rat. In these studies, we
cross linked ABA directly to the renal parenchyma by intra-
arterial perfusion of the left kidney with diazotized arsaniic
acid. This procedure introduces haptenic groups onto multiple
cell surface molecules and obviates the need for complex
intracellular antigen processing steps. The immune response
and the renal injury were studied at various time intervals in
control rats and animals pre-immunized with the hapten conju-
gated to a carrier protein. The expression of a disease process
mediated exclusively by antibodies directed against ABA was
studied by passive administration of hyperimmune rat serum to
a separate group of animals with planted ABA. The participa-
tion of cell-mediated immune processes was verified by adop-
tive transfer of T cells obtained from the lymph nodes of
immune animals.
Animals
Male Brown Norway rats weighing between 140 and 180 g
were obtained from Charles River Breeding Co. (Wilmington,
Massachusetts, USA). The experimental animals in this study
were handled and maintained in accordance with the guidelines
of the Committee on Animals of the Harvard Medical School
and those prepared by the Committee on Care and Use of
Laboratory Animals of the Institute of Laboratory Animal
Resources, National Research Council.
Preparation of ABA for intrarenal perfusion and coupling to
cells
Benzenearsonate diazonium (40 mM) was prepared as de-
scribed by Bach et at [31]. For this purpose, 241 mg para-
Arsaniic acid (Eastman Kodak Co., Rochester, New York,
USA) was solubilized in 24 ml of distilled water by the addition
of 3 ml of 1 N HC1. Diazotization was carried out by dropwise
addition of 0.8 ml of NaNO2 solution, 10 g/100 ml (Fisher
Scientific Co., Fair Lawn, New Jersey, USA). This amount
was, in general, sufficient to demonstrate free nitrite in the
solution by the instantaneous color change of potassium iodide-
starch paper (Fisher Scientific Co.). The solution was kept at
room temperature for 15 minutes and was re-tested for free
nitrite at the end of this reaction time. The diazotized arsanilic
acid was then placed under vacuum and used within four hours.
For intra-arterial perfusion of the left kidney, 4 ml of a 4 mM
solution of ABA was prepared by 1:10 dilution in borate
buffered saline (BBS; pH 8.40) and the final pH adjusted
between 8.1 and 8.2 with a pre-measured amount of 1 N NaOH.
A volume of 2 ml of this solution was immediately perfused into
the left kidney as described below.
Coupling of ABA to carrier proteins
p-Arsanilic acid (34.1 mg) was dissolved in 2.5 ml of I N HCI
and completely diazotized by slow, incremental addition of 1.3
ml of freshly prepared aqueous NaNO2, I g/100 ml. The
reaction was performed on ice. Keyhole limpet hemocyanin
(KLH) was obtained from Calbiochem Corp. (La Jolla, Califor-
nia, USA); 500 mg of the protein was resuspended in 20 ml of
BBS on ice and the pH adjusted to 9.2 by addition of 1 N NaOH.
The diazotized arsaniic acid was then added slowly over five to
seven minutes, while the pH was maintained between 9.0 and
9.3 by the addition of 1 N NaOH. The reaction mixture was
stirred for an additional 60 minutes and dialyzed for 48 hours
against phosphate buffered saline (PBS; NaC1 9 glliter, 5 mri
sodium phosphate buffer, pH 7.4). A similar protocol was used
for coupling ABA to other proteins.
Immunization of animals and preparation of anti-ABA
antiserum
Rats were immunized by a subcutaneous injection, in the
lower back at the root of the tail, with I mg ABA-KLH
emulsified in 0.2 ml of complete Freund's adjuvant (CPA)
containing 5 mg/ml of H37 RA Mycobactenum tuberculosis
(Difco Laboratories, Detroit, Michigan, USA). Animals were
challenged with ABA in the footpad or the left kidney between
S and 28 days following the immunization.
For adoptive cell transfer experiments, T cells were isolated
from the abdominal lymph nodes from animals immunized with
ABA-KLH in CFA 10 to 12 days earlier. For experiments
involving passive antibody administration, rat anti-ABA anti-
serum was obtained from Brown Norway rats following hyper-
immunization with ABA-KLH. For this purpose, rats were
immunized with ABA-KLH in CFA followed by two additional
booster subcutaneous immunizations of the immunogen in
incomplete adjuvant on days 14 and 28; serum was obtained by
bleeding under general anesthesia on day 35. An immunoglob-
ulin fraction was isolated with 50% saturated ammonium sul-
fate, resuspended in PBS at a final volume identical to the initial
amount of serum, and extensively dialyzed against PBS.
Measurement of DH to ABA in vivo
Animals immunized with ABA-KLH in CFA or control rats
that had received bovine serum albumin (BSA) in CFA were
challenged at various time points for determination of DH to the
hapten. We adapted the procedure of footpad challenge de-
scribed by Bach et al for the mouse [31]. For this purpose,
pre-injection measurements of both hind leg footpads were
performed with an Mitutoyo engineer's caliper calibrated in
1/100 mm (Harbor Tool Supply, Westwood, Massachusetts,
USA). Left and right hind legs were then injected randomly
with either 50 p.! of 10 m activated ABA in BBS or 50 p.1 of
BBS alone. The magnitude of the DH reaction was then
expressed as the increment in footpad thickness, a value that
can be compared to the contralateral measurement or to the
reaction in control animals immunized with BSA in CFA. Other
immunized animals were also challenged with an irrelevant
antigen which was used as a specificity control. All values were
the average of triplicate measurements performed without
knowledge as to the type of injection in any given footpad or as
to the immune status of the animal.
Histologic changes in the footpads were assessed following
standard light microscopic techniques.
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Fig. 1. Structural findings after ABA challenge of the left kidney. A and B. The pattern of distribution of ABA in the kidney by direct
immunofluorescence microscopy, at 24 hours after perfusion. Notice diffuse binding to basement membranes and to cell surfaces, as indicated by
the brush border staining of the proximal tubule cells in B. (direct immunofluorescence microscopy with fluorescein-5-isothiocyanate-labeled rabbit
anti-ABA). C. The histologic findings 5 days after ABA perfusion of the kidney in a control animal, immunized with CFA alone. The interstitium
is free of inflammation and the glomeruli appear normocellular. D. An area of the cortex of the left kidney in an animal pre-immunized with
ABA-KLH and challenged with ABA 5 days prior. Notice the diffuse granulomatous inflammation of the renal interstitium with widespread
destruction of tubular profiles. The inflammatory reaction is composed predominantly of mononuclear cells and is rich in epithelioid cells and
multinucleated giant cells. E. The detail of the glomerular injury at high power on day 5 after challenge. The granulomatous inflammation has
resulted in the formation of a cellular crescent, with focal destruction of Bowman's capsule by an infiltrate rich in giant cells. F. The binding of
rat IgO in the renal cortex in an animal with active disease at day 5. Notice minimal glomerular binding of immunoglobulins. There is no deposition
of IgG in the interstitium or along the tubular basement membrane. (Magnification: A, C, D, and F = 140x; B and E = 350x).
Assessment of DH to ABA in vitro by T cell proliferation
assay
The capacity of T cells to proliferate in response to antigen
presenting cells exposed to ABA was determined by 3H thymi-
dine incorporation using a method modified from Neilson et al
[20] and Ulich, Bannister and Wilson [44]. Briefly, cells har-
vested from draining lymph nodes of animals immunized 10
days earlier with ABA-KLH in CFA or CFA alone were
depleted of B cells by indirect panning with rabbit anti-rat
immunoglobulin antibodies [45] and resuspended in RPMI 1640
containing 2 mrvi L-glutamine, 10 mtt HEPES, 5 X l0 M
2-mercaptoethanol, and 5% fetal calf serum. 2 x l0 cells were
resuspended in 0.2 ml of complete medium and cultured in
microtiter wells in the presence of Concanavalin A (2.5 p.g!ml)
or various antigens at a concentration of 10 pgIml. The cells
were cultured for 72, 96, or 120 hours and pulsed for the last 24
hours with 1 CiJml of tritiated thymidine. Nuclei were col-
lected with a PHD cell harvester (Cambridge Technology,
Cambridge, Massachusetts, USA) and the p radiation mea-
sured. Each experimental setting was replicated in 12 separate
wells.
Assessment of the humoral response
Antibody titers were determined by solid phase RIA in
microtiter plates. For this purpose, round-bottomed microwell
polyvinyl chloride plates (Dynatech Laboratories, Inc., Chan-
tilly, Virginia, USA) were coated overnight at 4°C with 10 zg/m1
ABA-BSA in a Na2CO3/NaHCO3 buffer, pH 9.6, washed with
PBS-Tween, and incubated for two hours in a humidified
chamber at room temperature with increasing dilutions of
serum in PBS containing ovalbumin (0.5 gIlOO ml). Following
repeated washings, the wells were incubated with '251-labeled
rabbit anti-rat immunoglobulin (2 x l0 cpm!well) for two
hours, washed repeatedly, and the bound radioactivity deter-
mined with a y counter. A positive titer at any given dilution
was defined as a value equal or greater than 3 X background
radioactivity obtained with pre-immune rat serum at a similar
dilution.
A solid-phase ELISA system was used to evaluate the
isotype class response against ABA. Plates were coated with
ABA-BSA and incubated with rat serum as described above.
The plates were washed and incubated with either horseradish
peroxidase labeled sheep anti-rat IgG (The Binding Site, San
Diego, California, USA) or rabbit anti-rat 1gM (Zymed Labo-
ratories, South San Francisco, California, USA). The bound
secondary antibodies were visualized using o-phenylenedia-
mine, and the reaction was measured spectrophotometrically at
a wavelength of 492 nm using a Bio-Tek EL3 11 automatic plate
reader with KinetiCaic 2.03 software (Bio-Tek Instruments,
Inc., Winsooki, Vermont, USA). A positive titer was defined as
the dilution at which the 0D492 was at least 0.1 units greater
than that obtained with a normal rat serum at a similar dilution.
Using purified rat immunoglobulins from Zymed Laboratories
in a solid phase ELISA, we found that the sheep anti-rat IgG
preparation recognized all rat IgG subclasses and, to some
extent, 1gM. The rabbit anti-rat 1gM reagent was specific for
1gM. Thus, the antibody response information is presented as
titers of 1gM and IgG + 1gM.
Active disease model
Brown Norway rats were pre-immunized with either ABA-
KLH in CFA or with CFA alone. Ten days after the primary
immunization, the left kidney was perfused through the renal
artery successively with 1 to 2 ml PBS containing 0.05 mg/ml
verapamil, 2 ml of freshly activated ABA (4 m solution in
borate buffered saline solution at pH 8.1), and 1 ml of PBS!
verapamil. For this purpose, the left renal vessels were identi-
fied and isolated. A loose snare was placed around the left renal
vein and the abdominal aorta, between the superior mesenteric
artery and the left renal artery. The left renal artery was then
canulated with a 30 gauge needle, while the snares around the
aorta and the renal vein were closed. Ex vivo perfusion oc-
curred at a constant flow rate of 1.1 mI/mm. The effluent was
drained through a puncture of the temporarily ligated left vein
to minimize exposure of other organs and blood elements to the
hapten. Re-perfusion occurred promptly within one to two
minutes after release of ligatures and hemostasis. The total
ischemia time to abdominal organs was less than 12 minutes.
Animals were sacrificed after 4, 24, 48, and 120 hours after
intraarterial perfusion with the hapten. The left (ABA-perfused)
and right (non-perfused) kidneys were processed for standard
immunofluorescence, light, and electron microscopy, as de-
scribed previously [46, 47]. Fluorescein-labeled antibodies
against ABA, rat IgG, and rat C3 were utilized for direct
immunofluorescence microscopy. Infiltrating inflammatory
cells were identified by standard peroxidase-immunohistochem-
istry as described previously [48]. Briefly, coronal kidney
sections were frozen in liquid nitrogen and sectioned in a
cryostat at 4 to 6 m. Sections were fixed in acetone for 10
minutes, washed in PBS, and incubated for one hour with the
optimally diluted primary monoclonal antibody. Sections were
washed repeatedly and incubated with peroxidase-conjugated
rabbit anti-mouse IgG (Dako Corp. Santa Barbara, California,
USA) diluted appropriately in PBS. Peroxidase activity was
detected using H202 and diaminobenzidine (DAB, 6 mg/ml in
0.1 M Tris!saline buffer at pH 7.6 containing 0.03% H202).
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Sections were washed, lightly counterstained with hematoxy- T cell subsets and against monocyte/macrophages. OX-8 (spe-
lin, dehydrated, cleared, and mounted in synthetic resin. We cific for suppressor T cells) and W3/25 (recognizing T helper
utilized unlabeled mouse monoclonal antibodies against various cells) were a gift from Dr. Alan F. Williams (University of
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Oxford, Oxford, UK). R73, a monoclonal antibody directed
against the a,f.-T cell receptor produced by Hunig et a! [49],
was provided by Dr. Edgar Milford (Boston, Massachusetts,
USA). EDI, which recognizes rat monocytes/macrophages
[501, was purchased from Bioproducts for Science (Indianapo-
lis, Indiana). The frequency of each subset of infiltrating inflam-
matory cells was estimated semiquantitatively on mid-coronal
sections of the kidney.
The extent of cortical renal tissue involved by the inflamma-
tory infiltrate was estimated by planimetry on standard paraffin
sections stained with hematoxylin and eosin, utilizing a com-
puterized morphometric unit (Zeiss Videoplan, Carl Zeiss Inc.,
New York, NY, USA). For this purpose, two whole mount
coronal sections of each right and left kidneys were photo-
graphed at low magnification, and the renal cortex and the areas
of active inflammation were identified under light microscopic
examination at medium power and mapped onto the photo-
graphs. The extent of injury in each animal was then expressed
as a percent ratio of cortex involved by the inflammatory
process.
Passive disease model: Adoptive transfer of T cells
Animals were immunized with CFA alone and the left kidney
was perfused with ABA as described above. T lymphocytes
were obtained from draining lymph nodes of syngeneic donors
actively immunized with ABA-KLH in CFA 10 to 12 days
earlier. The cell suspension was depleted rigorously of B cells
by standard panning techniques [45] as described above. T cells
were then administered either systemically by the intravenous
route (ito 5 x 108 cells) or directly into the renal cortex of left
(ABA-perfused) and right (non-perfused) kidneys (5 x 106 cells)
[8, 18, 261. The effect of adoptive transfer of T cells on DH to
ABA, as measured by standard footpad swelling, was also
determined in a group of six rats. A separate group of animals
prepared and perfused in a similar fashion were injected with
panned T cells obtained form syngeneic donors immunized with
unmodified KLH in CFA. Kidneys were studied for structural
alterations five to six days following the administration of cells.
Passive disease model: Transfer of antibodies
For these experiments, animals were injected with CFA
alone 10 days earlier, and their left kidneys were perfused with
ABA as described above. One group of animals received a
single dose of high-titered antibody preparation (1 ml i.v., titer
1:65,536) one hour following the perfusion procedure. Animals
were sacrificed either 3 or 120 hours following antibody admin-
istration. A second group of experimental animals received
antibodies on four consecutive days (1 ml i.v./day) and were
sacrificed on day five. Structural studies were performed as
described above.
Results
Active disease model in the kidney
Following perfusion of the left kidney with activated ABA
under the conditions described above, the hapten was found to
bind uniformly to the elements of the glomerular capillary wall,
peritubular capillaries, tubule cell surfaces, and tubular base-
ment membranes when analyzed by direct immunofluorescence
microscopy with rabbit anti-ABA antibodies (Fig. 1, A and B).
The non-perfused right kidney did not show ABA reactivity.
After ABA perfusion, control CFA animals showed minimal
cortical abnormalities (Fig. 1C), with occasional foci of tubular
necrosis that, on day 5, appeared as small areas of interstitial
widening and minimal inflammation (not illustrated). Quantita-
tive assessment by planimetric measurement of such areas on
day 5 revealed an average of 8.1 3.8% (N = 10 rats) of cortical
tissue involved by such damage. These lesions tended to
resolve over the following two weeks with reduction of the
involvement to 3.4 0.9% by day 12 (N = 9 rats), This damage
was felt to represent ischemic injury of the perfusion process
since similar damage could be reproduced by temporary ligation
of the left renal artery for 15 to 30 minutes.
However, in animals pre-immunized with ABA-KLH in
CFA, direct coupling of ABA to the left kidney resulted, by 24
hours, in a mild but rather diffuse inflammatory cell infiltration
of the interstitium and glomeruli. The infiltrate was composed
predominantly of polymorphonuclear leukocytes, lymphocytes,
and other mononuclear inflammatory cells. The inflammatory
infiltrate became much more intense and mononuclear in char-
acter in the following days. By day 5, the process was distinctly
granulomatous, with massive destruction of cortical elements
by an infiltrate composed predominantly of epithelioid and giant
cells (Fig. lD). Isolated areas in some animals were spared by
this inflammation, presumably due to uneven and incomplete
delivery of the hapten to such areas during the perfusion
procedure. An average of 71.5 5.2% (N = 22 rats) of the
cortical area was involved by the granulomatous inflammatory
process. Structural abnormalities in glomeruli included intra-
capillary hypercellularity, crescent formation, and periglomer-
ular granulomatous reactions (Fig. 1E). Binding of rat immuno-
globulins or complement was minimal within glomeruli and
undetectable at the level of the tubulointerstitial compartment
when examined by direct immunofluorescence microscopy
(Fig. IF). The right unperfused kidney remained histologically
normal.
Immunohistochemistry was performed on frozen sections to
determine the phenotype of infiltrating cells. The results are
summarized in Table 1. Within two hours of the planting of
ABA into the left kidney of pre-immunized rats, small numbers
of R73 + (cells bearing the a,/3 T cell receptor) were identified in
the early infiltrate. Several W3/25+ cells (T helper/inducer
cells, macrophages, thymocytes) and OX8+ cells (cytotoxic/
suppressor T cells, NK cells, thymocytes) were identified as
well; a few monocytes/macrophages (ED! +) were also present.
By 24 hours, the R73 + cells had increased modestly, and the
predominant cell type was the monocyte/macrophage. The
infiltrate was also enriched in OX8 + and W3/25 + cells at this
time. The inflammatory infiltrate became much more diffuse
and intense over the following three days, with a great prepon-
derance of ED1 + monocytes/macrophages by day 5.
Significant proteinuria did not develop in these animals.
Serum levels of creatinine and urea nitrogen were not measured
since we did not anticipate noticeable changes in this unilateral
model of interstitial disease.
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Table 1. Phenotype of infiltrating inflammatory cells in the kidney at various time points after challenge with ABA
Time
Ce11 type
R73 T (a43) W3/25 TM 0X8 T5 + NK EDt Mon/Mac
2hours +to++ + Oto±
iday ++to+++ ++ ++
2days +to++ +++to++++ +++to++++ +++to++++
3days ++to+++ +++to+++-i- +++to++++ +++to++++
5days ++to+++ ++++ ++++ ++++
Infiltrating cells were characterized by peroxidase-immunohistochemistry utilizing the following monoclonal antibodies: R73, which recognizes
the a,$ subunit of the T cell receptor, W3/25, which recognizes helper T cells, 0X8, which recognizes suppressor T cells and NK cells, and ED 1,
specific for monocytes/ macrophages. The frequency of cells reactive with any particular antibody is indicated semiquantitative in a scale from 0
to ++++.
Table 2. Footpad swelling after challenge with ABA in BN rats
Footpad swellint
ABA Vehicle
Immunization Day N challenge challenge'
ABA-KLH/CFA 6-8 9 37.8 4.3 6.2 1.6
ABA-KLH/CFA 9—10 15 110.3 15.7 5.6 1.4
ABA-KLH/CFA 11—14 12 220.3 13.3 7.0 1.7
ABA-KLH/CFA 21—28 6 118.5 11.3 8.0 0.8
PBS/CFA 6—21 20 14.1 1.9 3.9 0.8
a Increase in thickness at 24 hours post-challenge measured in 1/100
mm; values represent the mean 5Db PBS in contralateral hind leg of same animal
DH to ABA assessed in vivo by footpad response
The results of the in vivo assessment of DH by footpad
swelling are summarized in Table 2. Six to eight days following
immunization, the response to the hapten produced a moderate
and somewhat inconsistent increase in footpad thickness when
measured 24 hours after the challenge. No significant swelling
occurred in vehicle injected contralateral footpads (differences
of <10 x 10—2 mm), after challenge with an irrelevant antigen-
(data not shown), or after ABA challenge in animals immunized
with CFA alone (<20 x 10—2 mm). The degree of swelling
increased substantially in animals challenged on days 9 to 10
after immunization, reaching a peak of 220 13 x 10—2 mm
between days 11 and 14. As expected of a cell-mediated
response, the footpad swelling increased from 93 14 x 10—2
mm at day I after challenge to 129 13 x l0_2 mm on day 2 in
a separate group of animals tested on day 10 and followed for 48
hours.
Light microscopic assessment of footpads revealed a striking
perivascular leukocyte infiltration of the dermis and sub-dermal
tissues at the injection site 24 hours after the challenge, fol-
lowed, at 48 hours, by a characteristic granulomatous inflam-
mation (Fig. 2).
In vitro T cell proliferation as a measurement of DH
response to ABA
The results of these studies are summarized in Table 3.
Reactive cells were obtained from draining lymph nodes 10
days following immunization with ABA-KLH in CFA or con-
trol immunizations with CFA alone. T cells were depleted of B
cells by negative panning with rabbit anti-rat immunoglobulin
antibodies and incubated with various antigenic preparations.
Concanavalin A (Con A) stimulated T cell proliferation peaked
as early as day 3 in culture, as observed previously by other
investigators, while antigen-specific proliferation (ABA-BSA
and ABA-KLH) was maximal at days 4 or 5. Note the lack of
proliferation to the protein carrier BSA. In conjunction with the
in vivo footpad challenge data, these results indicate that the rat
is capable of developing a cell-mediated, delayed type hyper-
sensitivity to the hapten ABA.
Antibody response following ABA-KLH immunization
The titers of antibodies against ABA that developed in rats at
various times following active immunization with ABA-KLH
are graphically depicted in Figure 3. As can be observed from
this figure, most of the early anti-ABA activity in the serum is
due to the presence of 1gM antibodies, a subclass of serum
proteins with very restricted permeability across capillary walls
[Si]. An immunoglobulin fraction was isolated from the serum
of Brown Norway rats which had been hyperimmunized with
ABA-KLH for use in passive transfer experiments. This prep-
aration had an 1gM anti-ABA titer of 1 x l0 and a total
anti-ABA titer of greater than 1 x 106 (data not shown).
Passive transfer experiments
Our adoptive T cell transfer experiments indicate that the
lesions observed in the actively immunized rats are primarily an
expression of cell-mediated immune injury. CFA-immunized,
ABA-perfused animals received panned T cells isolated from
lymph nodes taken from ABA-KLH immunized animals. This T
cell purification step has consistently yielded preparations of
lymph node cells with less than 3% contamination of B cells.
Groups of animals were given either S x 106 T cells injected into
the subcapsular space of left (perfused) and right (unperfused)
kidneys or S x io T cells intravenously. Direct intrarenal cell
transfer (N = 4) resulted in focal interstitial inflammatory
infiltration composed predominantly of large (epithelioid)
mononuclear cells (Fig. 4A). The control right kidney showed
minimal focal tubular atrophy and slight expansion of the
interstitium in areas of cell injection. Systemic, intravenous T
cell transfer resulted in focal granulomatous infiltration (Fig. 4
B and C) affecting, however, only a relatively limited fraction of
the left renal cortex (less than 10%). The cell composition of
these infiltrates qualitatively resembled the lesions observed in
the actively immunized rats. Antibodies were not detected in
the tissue. This amount of tissue damage may seem relatively
minor compared to the results seen in animals with the active
immunization. However, a similar reduction of disease severity
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Fig. 2. Histopathology following ABA challenge in the footpad. A. The results 48 hours after ABA challenge in an animal pretreated with CPA
alone. The upper half of the light micrograph shows the normal epidermis and dermis. The lower half includes scant normal subcutaneous adipose
tissue and skeletal muscle. Notice complete absence of inflammation. B. Results in an animal pre-immunized with ABA-KLH, 24 hours after
footpad challenge with ABA. There is extensive inflammation of the vascular wall and diffuse edema of the dermis. C. The histological changes
48 hours after ABA challenge in a pre-immunized animal. The dermis is expanded by a prominent inflammatory infiltrate, as evidenced by
comparing the findings with those in panel A; the overlying epidermis is stretched and has lost the normal appearance of the rete pegs. D. The
details of the inflammatory infiltrate at higher magnification. The infiltrate is composed of mononuclear cells, with predominance of lymphocytes
and epitheioid cells, with occasional multinucleated giant cells. (Magnification: A = Mx; B = 160x; C = 58x; D = 400x)
following T cell transfer was reported by other investigators
working with rat models of autoimmune renal disease [18].
Passive administration of high titered rat anti-ABA antibody
preparation (1 ml of an Ig preparation, 1 hr after ABA perfu-
sion) resulted in minimal glomerular hypercellularity at three
hours or five days, at times when rat IgG was bound in a linear
pattern along the glomerular capillary wall (+ + +14+) and the
tubular basement membranes (+14+) (Fig. 5A). No significant
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Table 3. In vitro stimulation of T cells obtained from BN rats 10 days after immunization
Immunization
in vivob
Length of
in vitro
culturec
Proliferative responsesa
No
antigen BSA Con A ABA-KLH ABA-BSA KLH
Control 3 0,5 0.0 3.5 0.3 116.9 4 3.3 0.2 2.6 0.2 3.4 0.2
ABA 3 2.4 0.1 2.3 0.1 150.1 7 15.1 3.0 5.4 0.5 5.3 0.4
Control 4 2.4 0.2 2.2 0.2 25.4 1 2.5 0.2 2.0 0.2 2.6 0.1
ABA 4 2.8 0.1 3.3 0.2 33.2 2 35,3 5.0 10.7 2 24.0 4.0
Control 5 2.1 0.1 2.1 0.1 8.4 0,5 2.2 0.1 2.4 0.2 2.4 0.1
ABA 5 4.2 0.3 3.7 0.5 20.4 2 39.8 3 20.4 4 45.0 6.0
a cpm x l0; values represent the mean scM; N = 12
"Control animals received PBS in CFA; ABA animals received ABA-KLH in CFA
In days
0
10 15 21
Time, days, post-immunization
Fig. 3. Time course of the antibody response in animals pre-immu-
nized with ABA-KLH. The solid line depicts the titer due to combina-
tion of antibodies of the IgG and 1gM class. The dashed line shows the
declining 1gM antibody titer over 4 weeks. Most antibody activity
between days 10 and 15 can be accounted for by antibodies of the 1gM
class. In comparison, pre-immune titers are undetectable and the
hyperimmune serum (5 weeks after immunization with ABA-KLH in
CFA followed by two additional booster subcutaneous immunizations
of the immunogen in incomplete adjuvant on days 14 and 28) reveals a
titer of >6. The antibody titer depicted on the y axis is expressed as the
—log10 of the dilution that resulted in greater than 3 x background
counts.
inflammation was noted in these rats, but foci of tubular atrophy
with mild interstitial edema were observed by day 5 (N = 4).
When the passive administration of anti-ABA antibodies was
increased to 1 ml on four consecutive days (N = 3), small foci
of tubular dilatation and atrophy were again present, involving
25.8 9.6% of the cortex at day 5. The lesions were confined
predominantly to S3 segments and to the tubules within the
columns of Bertin. However, this level of passive antibody
administration also resulted in glomerular injury with a distinct
diffuse endocapillary proliferative pattern and focal and seg-
mental necrotizing glomerulitis (Fig. 5 B and C). Direct immu-
nofluorescence microscopy showed strong rat IgG and weak C3
binding to all basement membranes, in particular to the GBM,
peritubular capillaries, and tubular basement membranes, a
finding never observed in the active disease model. This strong
antibody binding, the presence of a diffuse endocapillary pro-
liferative and necrotizing glomerulitis, and the absence of
granulomatous lesions in animals with passive antibody admin-
istration clearly distinguishes this antibody-mediated process
from the disease induced in actively immunized animals or in
animals with adoptive transfer of immune cells. The nature of
the mild tubulointerstitial damage seen in some animals that
were given antibodies could be mediated by classic antibody
and complement-dependent processes, however, the similari-
ties with the lesions induced by transient ischemia to the kidney
are rather striking.
Discussion
These experimental studies were designed to investigate a
potential role of cell-mediated immune reactions to planted,
28 exogenous antigens or haptens in the development of renal
injury. Although cell-mediated processes have been assumed to
play key roles in the pathogenesis of antibody-independent
renal diseases in man, reliable experimental models that faith-
fuliy duplicate the structural and functional abnormalities of the
human conditions that sometimes ensue after re-exposure to an
exogenous antigen have not been developed. Our studies were
designed to demonstrate that constitutive cells of the renal
cortex can serve as targets for delayed type hypersensitivity.
These initial studies used an exogenous antigenic determinant
that does not require an intracellular processing step. To this
effect, our studies do not address directly the issue of cellular
uptake and intralysosomal processing of the antigen by renal
cells. Instead, we chose to focus first on the ability of the kidney
to become the target for ABA-specific T cells. We chose
azobenzenearsonate, a hapten used extensively in murine stud-
ies of the immune system. The immune response to this hapten
in the Brown Norway rat was evaluated at various levels. The
ability of such animals to mount a specific DH response was
assessed quantitatively and morphologically in the footpad of
immunized animals following challenge with hapten. Significant
footpad swelling occurred in pre-immunized rats 24 and 48
hours after challenge with hapten, and the tissue exhibited a
characteristic granulomatous inflammation. Direct planting of
the haptenic group in the renal cortex of a rat pre-immunized to
ABA resulted in the massive destruction of tubules by a
granulomatous interstitial inflammation. Periglomerular granu-
lomas with prominent giant cells and distinctive glomerular
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Fig. 4. Passive transfer ofT cells into naive animals. A. The structural
changes in the left renal cortex of the ABA-perfused kidney, 5 days
after local, subcapsular injection of a T cell preparation. A localized
granulomatous inflammatory infiltrate has partially destroyed the nor-
mal cortical architecture. B and C. The findings 5 days after systemic
transfer of T cells. Notice focal cortical inflammatory changes with a
distinctive granulomatous character, similar in appearance to the
changes seen in the active disease model shown in Figure 1 . (Magnifi-
cation: A and C = l4Ox; B = 56x)
after ABA perfusion. T lymphocytes, obtained from previously
immunized rats, exhibited antigen-specific proliferation in vitro,
and such cells were capable of transferring a similar disease
modality to naive rats in which ABA had been planted in the left
kidney. Although we have not explored in detail a possible
special strain susceptibility to ABA in the Brown Norway rat,
there is little evidence in the literature that would suggest that
this strain reacts to ABA immunization in any special way.
Although differences in susceptibility in rat strains to develop a
particular tissue response have been described, such genetic
factors have mainly been explored for the process of focal
glomerulosclerosis [52] and for antibody-dependent reactions
[53]. We have been able to replicate the foot pad reaction to
ABA in immunized rats of several strains (data not included).
Additional experiments were designed to determine if ABA-
specific antibodies could play a pathogenic role in this disease
model. Radioimmunoassays revealed a minimal 1gM response
to ABA 10 days following immunization. Such large immuno-
globulin molecules are known to have limited access to renal
structures [51], and this was reflected in the lack of demonstra-
ble binding of rat immunoglobulins in the glomeruli of animals
undergoing an active disease. To further investigate the patho-
genicity of anti-ABA antibodies, passive transfer experiments
were conducted. Antibodies were obtained from serum of
hyperimmunized rats and, in this preparation, most of the
anti-ABA activity was found in the IgG class. The antibody was
administered to naive animals in which ABA had been planted
in the left kidney. Unlike the active model in which minimal
immunoglobulin was bound to renal structures, passive admin-
istration of anti-ABA IgG resulted in the diffuse binding of rat
antibody to the renal basement membranes. The animals,
however, did not develop a granulomatous inflammation but did
exhibit a proliferative glomerular injury with focal necrotizing
glomerulitis ; such injury was not seen in the active disease
model. These studies suggest that antibodies alone played a
minor, if any, role in the granulomatous interstitial nephritis
seen in the active disease. We cannot rule out completely a
potentially permissive or synergistic role of antibodies in the
pathogenesis of the active disease model since the actively
immunized animals clearly responded to the ABA challenge
with a more aggressive and extensive injury to the kidney.
Additional unexplored mediator systems may be up-regulated
in this setting and may play a critical role in the heightened
inflammatory response seen in the active model.
The model of renal injury describe by us utilizes a hapten
which was directly coupled to cell surface determinants, thus
most likely eliminating the need for intracellular processing of
crescents were also observed. Phenotypic characterization of antigen and re-expression of epitopes on the cell surface in the
the infiltrating cells demonstrated that both T cells and macro- context of MHC antigens. These studies demonstrated that
phages begin to accumulate in the renal cortex within two hours renal structures can serve as targets of a cell-mediated immune
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Fig. 5. Passive transfer of antibodies into naive animals. A. Diffuse
IgG binding along the glomerular basement membranes in a character-
istic linear pattern of distribution, 24 hours after a single injection of the
antiserum (direct immunofluorescence microscopy with fiuorescein-5-
isothiocyanate-labeled rabbit anti-rat Igo antibodies). B. Cortical
changes at day 5 after a single antibody injection. Notice minimal
glomerular hypercellularity and tubular changes characterized by mild
to moderate distention of the lumen and focal reduction in cell height of
the epithelium. These tubular changes most likely are part of the
recovery phase of ischemic injury induced during the interaction
between the tissue-bound hapten and the antibodies. C. Glomerular
changes 5 days after daily administration of antibodies. There is
prominent glomerular hypercellularity and a central area of fibrinoid
necrosis of the glomerular tuft, (Magnification: A and B = l4Ox; C =
350x).
sangial cells have the capacity to process and present complex
antigens to T cell hybridomas [5]. Tubular cells in culture have
also been shown to have the capacity to process and present
complex antigens [2—4].
Over the past few years, several investigators have reported
on the antigen presenting capacity of several non-lymphoid cell
types originally not thought of as having this function. To this
effect, Pober and colleagues were able to show that cultured
endothelial cells can up-regulate class II MHC antigens under
the influence of interferon-y and act effectively in antigen
presentation [54—58]. Others have also shown similar MHC
antigen responses to cytokines and immune regulatory capacity
for epithelial cells derived from the intestine [59—63], the
thyroid gland [64—67], pancreatic 13 cells [68], the thymus [69,
70], and the skin [71—74]. Although many of these studies were
performed on cultured cells and used relatively unregulated T
cell hybridomas or cells from cloned T cell lines and could be
criticized on this basis, our current studies clearly suggest that
such processes also occur in the intact animal. It is difficult to
prove, in this setting, that the primary antigen presentation
event is initiated by tubular epitheial cells and cells intrinsic to
the glomerular microcirculation since professional antigen-pre-
senting cells, such as macrophages, are always present in the
renal parenchyma. These studies, viewed in the context of the
previously quoted cell culture experiments, strongly suggest an
antigen presenting capacity for kidney cells other than profes-
sional macrophages.
The ABA-induced nephritis described here represents the
first attempt to model acute interstitial nephritis seen in hu-
mans, a process in which, as a rule, the participation of
antibodies or immune complexes has only rarely been docu-
mented. Such an inflammatory process is often the conse-
quence of an exposure to therapeutic agents such as antibiotics,
non-steroidal anti-inflammatory agents, or other drugs. Most
often this tissue reaction in humans involves a mononuclear cell
infiltration of the tubulointerstitial compartment, however, oc-
casionally a granulomatous inflammation is seen instead, as in
our model system. The precise mechanisms and mediator
systems responsible for either a lymphocytic or a granuloma-
tous tissue response are currently only incompletely explored.
Differences in the type of T cells elicited after the active
immunization, variations in the capacity of the target cells to
attack, although the precise Identity 01 tne initiating antigen- express or up-regulate certain histocompatibiity molecules,
presenting cell in this model remains currently undetermined, and other local factors may be responsible for this variability in
We have previously shown that glomerular epithelial and me- the tissue expression. The capacity of the kidney to concentrate
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the ultrafiltrate and the presence of various transport systems
within the tubule cells may result in drug concentrations within
intrinsic renal cells that could exceed that seen in other organs
by orders of magnitude. The kidney, therefore, becomes an
ideal candidate for toxic and potentially immune-mediated
injury. Patients with drug-induced acute interstitial nephritides
are usually afflicted by a disease that may have systemic
symptoms but with an inflammatory reaction that is limited to
the kidney. If this reaction were exclusively triggered by
professional antigen presenting cells without the participation
of intrinsic renal cells one would expect to find cell-mediated
immune reactions and an accompanying mononuclear cell in-
flammation in areas of the body particularly rich in antigen
presenting cells and not just an inflammation limited to the
tubules and the interstitial area. This observation, together with
the evidence provided by our studies, suggests that the kidney
offers a unique environment for immune-mediated reactions.
We propose that the concentrating function of the kidney and
potentially an immune-modulatory and an antigen presenting
capacity of intrinsic renal cells contribute significantly to the
observed propensity of the kidney to be involved in drug-
induced and cell-mediated inflammatory disease processes.
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